文献类型：期刊文献

中文题名：加味逍遥散治疗肠易激综合征的系统评价

英文题名：Evaluate of Jiawei Xiaoyao San for Irritable Bowel Syndrome

作者：郑富杰[1];刘海峰[1];李昕妍[1];王素梅[1];顾静[1]

第一作者：郑富杰

机构：[1]甘肃中医学院,兰州730000

第一机构：甘肃中医药大学

年份：2015

卷号：21

期号：9

起止页码：212

中文期刊名：中国实验方剂学杂志

外文期刊名：Chinese Journal of Experimental Traditional Medical Formulae

收录：CSTPCD;;北大核心:【北大核心2014】；CSCD:【CSCD_E2015_2016】；

语种：中文

中文关键词：肠易激综合征;加味逍遥散;系统评价

外文关键词：irritable bowel syndrome; Jiawei Xiaoyao San; systematic review

摘要：目的:系统评价加味逍遥散治疗肠易激综合征(IBS)的疗效与安全性。方法:计算机检索VIP,CNKI,万方,CBMdisc,收集以加味逍遥散为干预措施治疗肠易激综合征的随机对照试验,按Cochrane系统评价方法,评价纳入研究的方法学质量并提取有效数据进行Meta分析。结果:共纳入17个随机对照试验,包括1 542例肠易激综合征患者。Meta分析结果显示,加味逍遥散改善IBS症状及体征的总有效率优于其他治疗方法,且复发率低于对照组,比较结果显示RR(95%CI)分别为[1.31(1.24,1.38),P<0.000 01],[0.33(0.22,0.49),P<0.000 01],缺乏对加味逍遥散不良反应及长期副作用的报告。结论:这篇系统评价显示加味逍遥散对肠易激综合征的疗效优于其他治疗方法,但由于纳入文献质量不高,存在较大的偏倚风险,缺乏随访或随访资料不完善,不能评价加味逍遥散的远期疗效和安全性,使其对肠易激综合征临床治疗的指导意义受到限制。
Objective： The aim of this study was to evaluate the efficacy and safety of Jiawei Xiaoyao San for irritable bowel syndrome. Method： We searched the VIP, CNKI, Wanfang and China biology medicine disc （CBMdise） databases. Randomized controlled trials of clinical therapeutic studies on Jiawei Xiaoyao San for irritable bowel syndrome were included. The quality of included studies was evaluated and Meta-analysis was performed. Result： In this study, 17 trials involving 1 542 patients were included. Meta-analysis indicated that Jiawei Xiaoyao San was lower in the recurrence rate and more effective than other drugs in improving symptoms and signs of irritable bowel syndrome. The RR value （95% CI） were L RR = 0.33, 95% CI （0.22, 0.49）, P 〈 0.000 01] and [RR = 1.31, 95% CI （1.24, 1.38）, P 〈 0.000 01], respectively. The most included researches did not report adverse reactions. Conclusion： Based on this review, Jiawei Xiaoyao San is effective for irritable bowel syndrome. However, the evidence is not strong enough due to the low quality of included trials. Further, large-sample and multi-center studies are needed.